Fighting Dengue Fever: Takeda and Biological E Join Forces for Vaccine Production

Hyderabad, February 28th, 2024 – In a crucial development in the global battle against the mosquito-borne dengue fever virus, Japanese pharmaceutical giant Takeda announced Tuesday its partnership with India’s Biological E Limited to ramp up manufacturing of Takeda’s dengue vaccine called TAK-003.

This collaboration aligns with the World Health Organization’s 2030 target to reduce dengue fatalities to zero through increased vaccine access in endemic regions like India and Southeast Asia, home to 1.3 billion at-risk people.

Under the agreement, Biological E will scale up its Hyderabad facility to produce 50 million vaccine doses annually, supporting Takeda’s goal of reaching 100 million doses per year within the decade.

“This strategic manufacturing alliance with Biological E will substantially boost our capacity to supply TAK-003 globally,” said Gary Dubin, President of Takeda’s Vaccine Unit. “Together, we can help stop the spread of this rapidly emerging disease in India and beyond.”

Telangana Chief Minister Anumula Revanth Reddy welcomed the Takeda-Biological E venture that will spur high-tech biomanufacturing and high-skill jobs in the state. “Hyderabad will host the facility that manifests this visionary partnership to make the dengue vaccine accessible for millions,” Reddy stated.

With dengue spreading faster than any other mosquito-borne virus, public health experts hailed the development as a “game-changing” collaboration to battle a top global health threat.

Related Posts